WO1999009828A1 - Traitement de la phobie sociale - Google Patents

Traitement de la phobie sociale Download PDF

Info

Publication number
WO1999009828A1
WO1999009828A1 PCT/US1998/017210 US9817210W WO9909828A1 WO 1999009828 A1 WO1999009828 A1 WO 1999009828A1 US 9817210 W US9817210 W US 9817210W WO 9909828 A1 WO9909828 A1 WO 9909828A1
Authority
WO
WIPO (PCT)
Prior art keywords
social phobia
apomorphine
social
dopaminergic
administered
Prior art date
Application number
PCT/US1998/017210
Other languages
English (en)
Inventor
Ragab El-Rashidy
Bruce Ronsen
Ashraf Youssef
Original Assignee
Pentech Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals, Inc. filed Critical Pentech Pharmaceuticals, Inc.
Priority to AU89155/98A priority Critical patent/AU8915598A/en
Publication of WO1999009828A1 publication Critical patent/WO1999009828A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Abstract

La présente invention concerne un traitement convenant à des patients souffrant de troubles tels que la phobie sociale. Lorsqu'on a identifié un patient souffrant de phobie sociale, le traitement consiste à lui administrer une quantité suffisante d'un agoniste dopaminergique tel que l'hydrochlorure d'apomorphine.
PCT/US1998/017210 1997-08-25 1998-08-19 Traitement de la phobie sociale WO1999009828A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU89155/98A AU8915598A (en) 1997-08-25 1998-08-19 Method for amelioration of social phobia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92189397A 1997-08-25 1997-08-25
US08/921,893 1997-08-25

Publications (1)

Publication Number Publication Date
WO1999009828A1 true WO1999009828A1 (fr) 1999-03-04

Family

ID=25446140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/017210 WO1999009828A1 (fr) 1997-08-25 1998-08-19 Traitement de la phobie sociale

Country Status (3)

Country Link
AU (1) AU8915598A (fr)
WO (1) WO1999009828A1 (fr)
ZA (1) ZA987642B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519175B2 (en) 2017-10-09 2019-12-31 Compass Pathways Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HJORTH S., ENGEL J. A., CARLSSON A.: "ANTICONFLICT EFFECTS OF LOW DOSES OF THE DOPAMINE AGONIST APOMORPHINE IN THE RAT.", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR., ELSEVIER., US, vol. 24., 1 January 1986 (1986-01-01), US, pages 237 - 240., XP002913510, ISSN: 0091-3057, DOI: 10.1016/0091-3057(86)90344-8 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519175B2 (en) 2017-10-09 2019-12-31 Compass Pathways Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10947257B2 (en) 2017-10-09 2021-03-16 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10954259B1 (en) 2017-10-09 2021-03-23 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11149044B2 (en) 2017-10-09 2021-10-19 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11180517B2 (en) 2017-10-09 2021-11-23 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11447510B2 (en) 2017-10-09 2022-09-20 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11505564B2 (en) 2017-10-09 2022-11-22 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11629159B2 (en) 2017-10-09 2023-04-18 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11851451B2 (en) 2017-10-09 2023-12-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11939346B2 (en) 2017-10-09 2024-03-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11738035B2 (en) 2019-04-17 2023-08-29 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Also Published As

Publication number Publication date
AU8915598A (en) 1999-03-16
ZA987642B (en) 1999-02-24

Similar Documents

Publication Publication Date Title
Charney et al. Serotonin function and mechanism of action of antidepressant treatment: effects of amitriptyline and desipramine
Posey et al. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders
Zakrzewska et al. Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia.
Gualtieri Pharmacotherapy and the neurobehavioural sequelae of traumatic brain injury
Abdel-Hamid Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action
PAYKEL et al. Psychiatric side effects of antihypertensive drugs other than reserpine
KR100374924B1 (ko) 남성발기기능장애를회복시키고진단하기위한설하용량형
Posey et al. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders
Besson et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study
Emilien et al. Dopamine receptors—physiological understanding to therapeutic intervention potential
Donny et al. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans
US6232326B1 (en) Treatment for schizophrenia and other dopamine system dysfunctions
Cohn et al. Double-blind comparison of buspirone and clorazepate in anxious outpatients
Hall et al. Cocaine abuse and its treatment
Gillin et al. The effects of lisuride on mood and sleep during acute withdrawal in stimulant abusers: a preliminary report
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
Tutton et al. Current pharmacotherapies for cocaine abuse: a review
SORSCHER et al. Antidepressant-induced sexual dysfunction in men: Due to cholinergic blockade?
Houtsmuller et al. Transdermal selegiline and intravenous cocaine: safety and interactions
US20180221380A1 (en) Use of 5H-Dibenz/b,f/Azepine-5-Carboxamide Derivatives for Treating Fibromyalgia
Bitsios et al. The effects of clonidine on the fear-inhibited light reflex
Slenter et al. The effects of topical dorzolamide 2% and brinzolamide 1%, either alone or combined with timolol 0.5%, on intraocular pressure, pupil diameter, and heart rate in healthy cats
Smarius et al. Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa
ISBELL et al. Studies on lysergic acid diethylamide (LSD-25): III. Attempts to attenuate the LSD-reaction in man by pretreatment with neurohumoral blocking agents
BG62876B1 (bg) Използване на мелатонин за лечение на пациенти,страдащи от лекарствена зависимост

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999514403

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase